Positive impactCompany
CEPI funds Pune’s Immunoscript for “freezer-free” RNA vaccine
BusinessLine 2 hrs ago·9 Sept 2026, 3:02 pm
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced funding for Pune-based Immunoscript. The startup is developing a novel RNA vaccine platform designed to be stable at room temperature, eliminating the need for ultra-cold storage.
This technology is significant for India's vaccine landscape. By removing strict cold-chain requirements, it could lower distribution costs and expand access to remote areas. It also marks a step forward for indigenous mRNA capabilities in the country.
Investors should monitor the progress of clinical trials and regulatory approvals. The success of this 'freeze-free' approach could have broad implications for the broader biotechnology sector and global vaccine logistics.
Excerpt from BusinessLine
Barely months into operation, Pune-based biotech company Immunoscript Life Science will receive up to $8.9 million (almost ₹85 crore) from the Coalition for Epidemic Preparedness Innovations (CEPI) towards developing “freezer-free” or thermostable RNA vaccines – useful for low-resource settings. CEPI stated that it…Read the original at BusinessLine
Key takeaways
- Category: Company.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
